Correction to “ HPV vaccination following cervical intraepithelial neoplasia grade 2 diagnosis and risk of progression”EriksenDO, KrogL, OstenfeldEB, et al. HPV vaccination following cervical intraepithelial neoplasia grade 2 diagnosis and risk of progression. Acta Obstet Gynecol Scand. 2026;105(2):377–385. doi:10.1111/aogs.70128.

In the originally published version of this article, the hazard ratio and adjusted hazard ratio estimates reported in Table 2 and Tables S1 and S2 contained minor numerical inaccuracies due to a specification error in the analysis code. The estimates have been corrected in the text below and the updated tables are provided. The revised hazard ratios are slightly lower in magnitude but remain consistent in direction. Confidence intervals, statistical inference, and the interpretation of the findings are overall unchanged, and the conclusion of the study remains unaffected. In the Abstract, the corrected Results are: We included 4585 women, of whom 583 (12.7%) were vaccinated within 6 months after CIN2 diagnosis. A total of 1391 (30.3%) progressed to CIN3+ during follow-up. The 5-year cumulative risk was 29.9% (28.5–31.3). Overall, no protective effect of vaccination after CIN2 diagnosis was found (aHR 1.19 1.02–1.38). Stratified analyses showed increased progression risk with vaccination among women <30 years, in the latest calendar period (2013–2020), and among women with high-grade index cytology; no significant difference in risk was observed in women ≥30 years, women with nonhigh-grade index cytology, or in the early calendar period (2007–2013). The second, third, and fourth paragraphs in the corrected Results section are: Among the 4585 women included, 1391 (30.3%) progressed to CIN3+ during follow-up. Cervical cancer was diagnosed in 18 women (0.4%). The 5-year cumulative risk of CIN3+ was slightly higher among vaccinated women (33.7% 95% CI: 29.8–37.6) compared to unvaccinated women (29.3% 95% CI: 27.9–30.8) (Table 2, Figure 2). After adjusting for confounders, HPV vaccination was associated with an increased risk of progression to CIN3+, with an adjusted hazard ratio (aHR) of 1.19 (95% CI: 1.02–1.38) compared to unvaccinated women. When stratifying by age at the time of CIN2 diagnosis, we found that HPV vaccination was associated with an increased risk of progression among women <30 years (aHR 1.24 95% CI: 1.04–1.48), whereas there was no difference between vaccinated and unvaccinated women when aged ≥30 years (aHR 1.14 95% CI: 0.85–1.53). When stratifying by calendar period, vaccinated women had an aHR of 1.16 (95% CI: 0.97–1.39) compared with unvaccinated women among those diagnosed between 2007 and 2012, whereas in the most recent period (2013–2020), the risk of progression to CIN3+ was slightly higher among vaccinated compared with unvaccinated women (aHR 1.34 95% CI: 1.01–1.78). When stratifying by index cytology, vaccinated women had an aHR of 1.13 95% CI: 0.89–1.42 compared with unvaccinated women among women with nonhigh-grade cytology and an aHR of 1.31 (95% CI: 1.07–1.60) among those with high-grade cytology at diagnosis (Table 2). Only 14 women (0.3%) were diagnosed with vulva HSIL+, VaIN2+, or AIN2+ after their CIN2 diagnosis, precluding us from calculating cumulative risk and HRs. In the first sensitivity analysis, where the exposure window was extended to 6 months before to 6 months after CIN2 diagnosis, estimates were slightly higher than in the main analysis, but it did not change the main conclusion (Table S1). When restricting the analysis to women vaccinated before their first follow-up visit, the overall estimate was similar (Table S2). Adjusting for maternal income and educational level instead of the women's own socioeconomic variables did not change overall findings (data not shown). We regret the error. Table S1. Risk of CIN3+ by HPV vaccination status overall and by age, year of diagnosis, and index cytology for women vaccinated 6 months before to 6 months after CIN2 diagnosis. Table S2. Risk of CIN3+ by HPV vaccination status overall and by age, year of diagnosis, and index cytology for women vaccinated before their first follow-up visit. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.